UGT1A1 genotyping: A predictor of irinotecan-associated side effects and drug efficacy?

Anti-Cancer Drugs

Volumn 20, Issue 10, 2009, Pages 867-879

  Schulz, Christoph ^a   Boeck, Stefan ^a   Heinemann, Volker ^a   Stemmler, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Colorectal cancer; Delayed diarrhoea; Drug metabolism; Efficacy; Gene polymorphism; Irinotecan; Neutropenia; Racial variability; Toxicity; UGT1A1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; BILIRUBIN; CARBOXYLESTERASE; DNA TOPOISOMERASE; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; OXALIPLATIN;

BILIRUBIN BLOOD LEVEL; BIOTRANSFORMATION; BLOOD TOXICITY; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; GENOTYPE; HOMOZYGOSITY; HUMAN; METASTASIS; NEUTROPENIA; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; BIOMARKERS, PHARMACOLOGICAL; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; CONTINENTAL POPULATION GROUPS; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC;

EID: 73349138231     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328330c7d2     Document Type: Review

References (133)

1. Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124:484-485.
2. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
3. Sachidanandam R,Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-933.
4. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29:596-600.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 1998; 279:1200-1205.
6. FDA. United States Food and Drug Administration: Camptosar label. http://www.fda.gov/cder/foi/label/2005/020571s024,027,028lbl.pdf. 2005
7. FDA. United States Food and Drug Administration: Invader UGT1A1 molecular assay 510(k) summary. http://www.fda.gov/cdrh/pdf5/K051824.pdf. 2005
8. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006; 24:4534-4538.
9. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002; 8:641-661.
10. Ulukan H, Swaan PW. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002; 62:2039-2057.
11. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
13. Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Borsellino N, et al. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol 2005; 16 (Suppl 4):iv56-iv60.
14. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-4875.
15. Douillard JY, Sobrero A, Carnaghi C, Comella P, Diaz-Rubio E, Santoro A, et al. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol 2003; 14 (Suppl 2):ii7-ii12. (Pubitemid 36874132)
16. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
17. Mitry E, Douillard JY, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15:1013-1017.
18. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-1214.
19. Wall M, Wani M, Cook C, Palmer K, McPhail A, Sim G. Plant antitumor agents. I. The isolation and structure of camptothecine, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88:3888-3890.
20. Oberlies NH, Kroll DJ. Camptothecin and taxol: historic achievements in natural products research. J Nat Prod 2004; 67:129-135.
21. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260:14873-14878.
22. Mathijssen RH, van Alphen RJ, Verweij J, LoosWJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182-2194.
23. Gelderblom HA, de Jonge MJ, Sparreboom A, Verweij J. Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs 1999; 17:401-415.
24. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997; 25:1157-1164.
25. Haaz MC, Rivory LP, Riche C, Robert J. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 1997; 356:257-262.
26. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-4191.
27. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
28. Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 1998; 286:578-583.
29. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A, et al.Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996; 56:3689-3694.
30. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501-1518. (Pubitemid 32202559)
31. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993; 84:697-702.
32. Sperker B, Backman JT, Kroemer HK. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clin Pharmacokinet 1997; 33:18-31.
33. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002; 72:265-275. (Pubitemid 35052985)
34. Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, et al. Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 2004; 76:567-578.
35. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7:255-269.
36. Maruo Y, Iwai M, Mori A, Sato H, Takeuchi Y. Polymorphism of UDPglucuronosyltransferase and drug metabolism. Curr Drug Metab 2005; 6:91-99.
37. McDonnell WM, Hitomi E, Askari FK. Identification of bilirubin UDP-GTs in the human alimentary tract in accordance with the gut as a putative metabolic organ. Biochem Pharmacol 1996; 51:483-488.
38. Bock KW, Gschaidmeier H, Heel H, Lehmkoster T, Munzel PA, Bock-Hennig BS. Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31:411-422.
39. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol 2003; 38:107-117.
40. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347:578-581.
41. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; 181-182:453-456.
42. Servedio V, d'Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, et al. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat 2005; 25:325.
43. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16:297-306.
44. Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, et al. Genetic polymorphisms of bilirubin uridine diphosphateglucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 2004; 19:1023-1028.
45. Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95:8170-8174.
46. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8:1049-1051.
47. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9:845-847.
48. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576-582.
49. Iyer L, Das S, Janisch L,Wen M, Ramirez J, Karrison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43-47.
50. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388.
51. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.
52. Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13:3269-3275.
53. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:3061-3068.
54. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10:5151-5159.
55. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91:678-682.
56. Font A, Sanchez JM, Taron M, Martinez-Balibrea E, Sanchez JJ, Manzano JL, et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003; 21:435-443.
57. McLeod HL, Parodi L, Sargent DJ, Marsh S, Green E, Abreu P, et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24: No. 18S (June 20 Supplement): Abstract No. 3520.
58. Seymour MT, Braun MS, Richman SD, Daly C, Thompson LC, Meade A, et al. Association of molecular markers with toxicity in a randomized trial of chemotherapy for advanced colorectal cancer (FOCUS). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24: No. 18S (June 20 Supplement): Abstract No. 2022.
59. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26:2690-2698.
60. Roth AD, Yan P, Dietrich D, Fiocca R, Bodoky G, Labianca R, et al. Does UGT1A1*28 homozygosity predict for severe toxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3-EORTC 40993-SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II-III colon cancer. Gastrointest Cancers Symp 2008; Abstract No. 277.
61. Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112:1932-1940.
62. Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99:275-282.
63. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23:4856-4865.
64. Hazama S, Nagashima A, Kondo H, Shimizu R, Araki A, Yoshino S, et al. A genetic UGT1A1 polymorphism oriented phase I study of irinotecan (CPT-11) and doxifluridine (5′-DFUR): an intermediate form of capecitabine for metastatic colorectal cancer (MCRC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24: No. 18S (June 20 Supplement): Abstract No. 3602.
65. Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:1439-1446.
66. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 2007; 47:78-86.
67. Fujiwara Y, Sekine I, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, et al. Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with Cisplatin and irinotecan. Jpn J Clin Oncol 2007; 37:358-364.
68. Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Vernillet L, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303-4312.
69. Kramar A, Gourgou-Bourgade S, Ychou M. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan. J Clin Oncol 2005; 23:650. Author reply 650-651.
70. Hoskins JM, Goldberg RM, McLeod HL. Irinotecan-induced neutropenia and UGT1A1*28: does dose matter? ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25: No. 18S (June 20 Supplement): Abstract No. 4023
71. Chiara S, Nobile MT, Tomasello L, Acquati M, Taveggia P, Murolo C, et al. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer. Anticancer Res 2005; 25:1391-1396.
72. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, et al. UGT1A7and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11:1226-1236.
73. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106: 1007-1016.
74. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99:1290-1295.
75. Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007; 25:2594-2600.
76. Innocenti F. UGT1A1 genotyping in patients undergoing treatment with irinotecan. Clin Adv Hematol Oncol 2005; 3:843-844.
77. Doyama H, Okada T, Kobayashi T, Suzuki A, Takeda Y, Mabuchi H. Effect of bilirubin UDP glucuronosyltransferase 1 gene TATA box genotypes on serum bilirubin concentrations in chronic liver injuries. Hepatology 2000; 32:563-568.
78. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9:341-349.
79. Liu J, Qu K, Sferruzza A, Bender R. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian polulations in the US: a genomic analysis of 138 healthy individuals. Anti-Cancer Drugs 2007; 18:693-696.
80. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C >T (P229L) found in an African-American. Drug Metab Dispos 2005; 33:458-465.
81. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12:725-733.
82. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97:1255-1259.
83. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C > A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007; 98:1461-1467.
84. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphismsin Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007; 17:497-504.
85. Ando Y, Fujita K, Sasaki Y, Hasegawa Y. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 2007; 9:258-262.
86. Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJ. Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 2002; 12:81-83.
87. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003; 31:108-113.
88. Zhang A, Xing Q, Qin S, Du J,Wang L, Yu L, et al. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J 2006; 7:333-338 [Epub 24 October 2006]
89. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75:501-515.
90. Kitagawa C, Ando M, Ando Y, Sekido Y,Wakai K, Imaizumi K, et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005; 15:35-41.
91. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 1998; 42 (Suppl):S31-S43.
92. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260:199-202.
93. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 2002; 62:446-450.
94. Lankisch TO, Vogel A, Eilermann S, Fiebeler A, Krone B, Barut A, et al. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 2005; 67:1732-1739.
95. Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V, et al. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 2008; 17:695-701.
96. Teng HC, Huang MJ, Tang KS, Yang SS, Tseng CS, Huang CS. Combined UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert's syndrome in Taiwanese adults. Clin Genet 2007; 72:321-328.
97. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62:608-617.
98. Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 2002; 93:591-597.
99. Huang MJ, Yang SS, Lin MS, Huang CS. Polymorphisms of uridinediphosphoglucuronosyltransferase 1A7 gene in Taiwan Chinese. World J Gastroenterol 2005; 11:797-802.
100. Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 2006; 34:1220-1228.
101. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24:2237-2244.
102. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004; 44:854-860.
103. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6:2012-2020.
104. Sai K, Kaniwa N, Ozawa S, Sawada JI. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4. Drug Metab Dispos 2001; 29:1505-1513.
105. Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, et al. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 2002; 30:391-396.
106. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004; 96:1585-1592.
107. Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, et al. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 2008; 62:529-537.
108. Van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008; 11:77-98.
109. Morishita Y, Fujii M, Kasakura Y, Takayama T. Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan. J Int Med Res 2005; 33:84-89.
110. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9:3246-3253.
111. Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 2000; 60:4725-4728.
112. Iyer L, Ramirez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ, et al. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 2002; 49:336-341.
113. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, et al. ATPDependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999; 55:921-928.
114. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 1997; 281:304-314. (Pubitemid 27203082)
115. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001; 288:827-832.
116. De Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81:42-49.
117. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecanpharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110:138-147.
118. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005; 59:415-424.
119. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008; 34:656-669.
120. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008; 14:1788-1796.
121. Allegra CJ, Benedetti JK. Don Quixote and the quest for personalized medicine. J Clin Oncol 2008; 26:2619-2620.
122. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-C11 F205, F220, F221 and V222 study groups. Br J Cancer 2000; 83:431-437.
123. Dranitsaris G, Shah A, Spirovski B, Vincent M. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. Clin Colorectal Cancer 2007; 6:367-373.
124. Yong WP, Ramirez J, Innocenti F, Ratain MJ. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 2005; 11:6699-6704.
125. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20:3122-3129.
126. Mirkov S, Komoroski BJ, Ramirez J, Graber AY, Ratain MJ, Strom SC, et al. Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos 2007; 35:228-233.
127. Van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005; 11:7800-7806.
128. Mannel M. Drug interactions with St John's wort : mechanisms and clinical implications. Drug Saf 2004; 27:773-797.
129. De Jong FA, van der Bol JM, Mathijssen RH, LoosWJ, Mathot RA, Kitzen JJ, et al. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity. Cancer Biol Ther 2007; 6:1368-1374.
130. Van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007; 25:2719-2726.
131. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94:1247-1249.
132. Dai Z, Papp AC,Wang D, Hampel H, SadeeW. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1:24.
133. Obradovic M, Mrhar A, Kos M. Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008; 9:539-549.